Explore
Targeting PI3K/mTOR signaling in cancer
Alexandre Arcaro
2014
0 Ungluers have
Faved this Work
Login to Fave
The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connection to cancer. Somatic or inherited mutations frequently occur in tumor suppressor genes (PTEN, TSC1/2, LKB1) and oncogenes (PIK3CA, PIK3R1, AKT) in the PI3K/mTOR pathway. The fact that the PI3K/mTOR pathway is deregulated in a large number of human malignancies, and its importance for different cellular responses, makes it an attractive drug target. Pharmacological PI3K inhibitors have played a very important role in studying cellular responses involving these enzymes. Currently, a wide range of selective PI3K inhibitors have been tested in preclinical studies and some have entered clinical trials in oncology. Rapamycin and its analogs targeting mTOR are effective in many preclinical cancer models. Although rapalogs are approved for the treatment of some cancers, their efficacy in clinical trials remains the subject of debate. Due to the complexity of the PI3K/mTOR signaling pathway, developing an effective anti-cancer therapy remains a challenge. The biggest challenge in curing cancer patients with various signaling pathway abnormalities is to target multiple components of different signal transduction pathways with mechanism-based combinatorial treatments.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 86 times via unglue.it ebook links.
- 5 - epub (CC BY) at Unglue.it.
- 5 - epub (CC BY) at Unglue.it.
- 26 - mobi (CC BY) at Unglue.it.
- 21 - epub (CC BY) at Unglue.it.
- 23 - pdf (CC BY) at Unglue.it.
Keywords
- Akt
- Cancer
- clinical trials
- medicine
- mTOR
- Phosphoinositide 3-kinase
Links
DOI: 10.3389/978-2-88919-244-1Editions